Acura Pharmaceuticals, Inc.  

(Public, NASDAQ:ACUR)   Watch this stock  
Find more results for ACUR
1.70
-0.02 (-1.16%)
Aug 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.70 - 1.72
52 week 1.56 - 3.52
Open 1.72
Vol / Avg. 11,860.00/26,542.00
Mkt cap 20.60M
P/E     -
Div/yield     -
EPS -0.86
Shares 11.83M
Beta 1.72
Inst. own 57%
Nov 2, 2016
Q3 2016 Acura Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Aug 9, 2016
Q2 2016 Acura Pharmaceuticals Inc Earnings Call
Aug 8, 2016
Q2 2016 Acura Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -1279.38% -58.10%
Operating margin -1198.05% -46.59%
EBITD margin - -38.88%
Return on average assets -107.03% -30.24%
Return on average equity -412.71% -77.04%
Employees 15 -
CDP Score - -

Address

616 N North Ct Ste 120
PALATINE, IL 60067-8121
United States - Map
+1-847-7057709 (Phone)
+1-847-7055399 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Acura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company's Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company's Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company's Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.

Officers and directors

Robert B. Jones President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Peter A. Clemens Chief Financial Officer, Senior Vice President, Secretary
Age: 62
Bio & Compensation  - Reuters
Robert A. Seiser CPA Vice President, Corporate Controller and Treasurer
Age: 51
Bio & Compensation  - Reuters
J. Bradley Rivet Vice President - Marketing
Age: 61
Bio & Compensation  - Reuters
Albert W. Brzeczko Ph.D. Vice President -Technical Affairs
Age: 58
Bio & Compensation  - Reuters
James F. Emigh Vice President - Corporate Development
Age: 59
Bio & Compensation  - Reuters
George K. Ross Independent Director
Age: 73
Bio & Compensation  - Reuters
William G. Skelly Independent Director
Age: 64
Bio & Compensation  - Reuters
Immanuel Thangaraj Independent Director
Age: 44
Bio & Compensation  - Reuters
Bruce F. Wesson Independent Director
Age: 72
Bio & Compensation  - Reuters